U.S. patent application number 13/897566 was filed with the patent office on 2013-10-03 for pulsatile peri-corneal drug delivery device.
The applicant listed for this patent is Alcon Research, Ltd.. Invention is credited to Bhagwati P. Kabra, Alan L. Weiner.
Application Number | 20130261569 13/897566 |
Document ID | / |
Family ID | 43828421 |
Filed Date | 2013-10-03 |
United States Patent
Application |
20130261569 |
Kind Code |
A1 |
Weiner; Alan L. ; et
al. |
October 3, 2013 |
Pulsatile Peri-Corneal Drug Delivery Device
Abstract
The present invention is directed to a pulsatile ophthalmic
peri-corneal drug delivery device. The device includes an annular
body and a mechanism for releasing multiple separate and distinct
doses of a therapeutic composition over an extended period of
time.
Inventors: |
Weiner; Alan L.; (Arlington,
TX) ; Kabra; Bhagwati P.; (Euless, TX) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
Alcon Research, Ltd. |
Fort Worth |
TX |
US |
|
|
Family ID: |
43828421 |
Appl. No.: |
13/897566 |
Filed: |
May 20, 2013 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
13012885 |
Jan 25, 2011 |
8469934 |
|
|
13897566 |
|
|
|
|
61298577 |
Jan 27, 2010 |
|
|
|
Current U.S.
Class: |
604/290 ;
604/298 |
Current CPC
Class: |
A61N 1/30 20130101; A61F
9/0017 20130101; A61F 9/0026 20130101; A61K 9/0009 20130101; A61K
9/0048 20130101; A61P 27/02 20180101 |
Class at
Publication: |
604/290 ;
604/298 |
International
Class: |
A61F 9/00 20060101
A61F009/00 |
Claims
1. An ophthalmic peri-corneal drug delivery device, comprising; an
annular body sized and shaped to reside upon a conjunctiva of a
human eye and extend substantially entirely about a cornea of the
human eye when the annular body is disposed upon the human eye; a
therapeutic composition associated with the annular body; and at
least one opening for releasing the therapeutic composition wherein
the therapeutic composition is released through the at least one
opening topically to the eye as multiple separate doses through
repeated release of one or more of a plurality of separate and
distinct units.
2. A device as in claim 1 wherein the therapeutic composition is
divided into the plurality of separate and distinct units within
the annular body.
3. A device as in claim 1 wherein the device, the annular body or
both include a contact surface that is shaped and sized to
correspond to and contact the conjunctiva of the human eye upon
application of the device to the eye.
4. A device as in claim 3 wherein the contact surface of the device
including all portions that contact the conjunctiva has a surface
area that is at least 77 mm.sup.2 and is typically no greater than
220 mm.sup.2.
5. A device as in claim 1 wherein the device has a volume that is
at least at least 14 mm.sup.3 and is no greater than 100
mm.sup.3.
6. An ophthalmic pericorneal drug delivery device, comprising; an
annular body sized and shaped to reside upon a conjunctiva of a
human eye and extend substantially entirely about a cornea of the
human eye when the annular body is disposed upon the human eye; a
therapeutic composition associated with the annular body wherein
the therapeutic composition is divided into a plurality of separate
and distinct units; a plurality of separate reservoirs, each of the
plurality of reservoirs containing a separate and distinct unit of
the plurality of units; and a plurality of openings separately and
respectively associated with the plurality of separate reservoirs
for providing fluid communication to the plurality of reservoirs;
and a plurality of doors for separately and respectively covering
the plurality of openings wherein each door of the plurality of
doors is opened at a separate and distinct point in time to provide
for separate release of the separate and distinct units over an
extended period of time.
7. A device as in claim 6 wherein the plurality of doors are formed
of an erodible material that is configured to erode is a manner
that allows the distinct units to exit the annular body at separate
and distinct periods of time.
8. A device as in claim 7 further comprising an electrical energy
source associated with the annular body and an anode and a cathode
associated with each of the plurality of openings wherein
electrical energy sources provide energy to the anode and cathode
to aid in eroding the erodible material of the doors.
9. A device as in claim 6 wherein the therapeutic composition
includes a prostaglandin.
10. A device as in claim 6 wherein the device, the annular body or
both include a contact surface that is shaped and sized to
correspond to and contact the conjunctiva of the human eye upon
application of the device to the eye.
11. A device as in claim 10 wherein the contact surface of the
device including all portions that contact the conjunctiva has a
surface area that is at least 77 mm.sup.2 and is typically no
greater than 220 mm.sup.2.
12. A device as in claim 11 wherein the device has a volume that is
at least at least 14 mm.sup.3 and is no greater than 100
mm.sup.3.
13. An ophthalmic pericorneal drug delivery device, comprising; an
annular body sized and shaped to reside upon a conjunctiva of a
human eye and extend substantially entirely about a cornea of the
human eye when the annular body is disposed upon the human eye; a
therapeutic composition associated with the annular body wherein
the therapeutic composition is disposed as multiple separate
distinct units in a single reservoir within the annular body; an
electromechanical device connected to the annular body; and at
least one opening for providing fluid communication between the
single reservoir and an environment external of the device wherein
the electromechanical device moves each unit to the at least one
opening at a separate point in time over an extended time
period.
14. A device as in claim 13 wherein each of the separate and
distinct units comprises a polymeric shell defining at least one
reservoir wherein the therapeutic composition is disposed in the at
least one reservoir of the polymeric shell of each of the separate
and distinct units.
15. A device as in claim 13 wherein the separate and distinct units
comprise a body with a therapeutic composition coated thereon.
16. A device as in claim 13 wherein the separate and distinct units
comprise a is polymeric matrix with therapeutic composition
dispersed throughout the matrix.
17. A device and in any of claims 13 through 16 wherein the
reservoir is annular and the separate and distinct units are
distributed about the reservoir.
18. A device and in claim 13 wherein the therapeutic composition
includes a prostaglandin.
19. A device and in claim 13 wherein the device, the annular body
or both include a contact surface that is shaped and sized to
correspond to and contact the conjunctiva of the human eye upon
application of the device to the eye.
20. A device as in claim 19 wherein the contact surface of the
device including all portions that contact the conjunctiva has a
surface area that is at least 77 mm.sup.2 and is typically no
greater than 220 mm.sup.2.
21. A device as in claim 20 wherein the device has a volume that is
at least at least 14 mm.sup.3 and is no greater than 100
mm.sup.3.
22. A method of treating an ophthalmic disease comprising:
disposing a device as in claim 1 on the conjunctiva of the eye.
23. A method as in claim 22 wherein the device is disposed and
maintained upon the eye without the use of any mechanical fastening
elements that extend into the eyeball.
24. A method as in claim 23 wherein the device is maintained upon
the eye for an extended period of time that is at least 24
hours.
25. A method of treating an ophthalmic disease comprising:
disposing a device as in claim 6 on the conjunctiva of the eye.
26. A method of treating an ophthalmic disease comprising:
disposing a device as in claim 13 on the conjunctiva of the eye.
Description
CROSS-REFERENCE TO RELATED APPLICATION
[0001] This present application is a divisional of U.S. patent
application Ser. No. 13/012,885 filed Jan. 25, 2011 which claims
priority to U.S. Provisional Patent Application No. 61/298,577,
filed Jan. 27, 2010, the entire contents of which are incorporated
herein by reference.
TECHNICAL FIELD OF THE INVENTION
[0002] The present invention relates generally to the field of
ocular devices, pharmaceutics, and methods of drug delivery to the
eye. More particularly, it concerns pulsatile peri-corneal ocular
devices for the sustained pulsatile delivery of a therapeutic
compound to the eye.
BACKGROUND OF THE INVENTION
[0003] The pharmaceutical industry has developed a variety of
techniques for delivering ophthalmic compositions, particularly
those that include therapeutic agents, to the eye. Typical
ophthalmic drug delivery techniques include topical application of
ophthalmic compositions to the eye (e.g., by drops directly onto
the eye) and intravitreal injections, which involve delivery of
ophthalmic compositions to the vitreous of the eye with a needle
(e.g., a syringe). Both of these techniques have drawbacks. One
particular drawback common to both of these techniques is the
frequency with which an individual must apply the ophthalmic
compositions to best treat ophthalmic maladies such as glaucoma,
age related macular degeneration (AMD) and others. Patients often
forget or otherwise fail to administer drops to their eyes and
patients can miss doctor appointments and fail to receive their
needed injections.
[0004] In view of these drawbacks, the pharmaceutical industry has
dedicated significant resources to the development of implantable
drug delivery devices that provide sustained delivery of ophthalmic
compositions and/or therapeutic agents to the eye. Such devices are
typically designed to provide a continuous supply of therapeutic
agent to the eye over an extended period of time.
[0005] Various ocular drug delivery implants have been described in
an effort to improve and prolong drug delivery. For example, U.S.
Pat. No. 3,949,750 discloses a punctal plug made of a
tissue-tolerable, readily sterilizable material, such as Teflon,
HEMA, hydrophilic polymer, methyl methacrylate, silicone, stainless
steel or other inert metal material. It is stated that the punctal
plug may be impregnated with ophthalmic medication or that the
punctal plug may contain a reservoir of the ophthalmic drug.
[0006] U.S. Pat. No. 5,053,030 discloses an intracanalicular
implant that can be used as a carrier or medium for distributing
medications throughout the body. U.S. Pat. No. 5,469,867 discloses
a method of blocking a channel, such as the lacrimal canaliculus by
injecting a heated flowable polymer into the channel and allowing
it to cool and solidify. The polymer may be combined with a
biologically active substance that could leach out of the solid
occluder once it has formed in the channel.
[0007] WO 99/37260 discloses a punctal plug made of a moisture
absorbing material, which is not soluble in water, such as a
modified HEMA. It is also disclosed that an inflammation inhibitor,
such as heparin, may be added to the material from which the
punctal plug is made.
[0008] U.S. Pat. No. 6,196,993 discloses a punctal plug containing
glaucoma medication. The medication is contained in a reservoir
within the plug. The reservoir is in fluid communication with a
pore through which the medication is released onto the eye.
[0009] U.S. Pat. No. 4,592,752 discloses a corneal drug delivery
device. The device is substantially the size and curvature of the
cornea upon which it is placed and it includes an aperture
substantially the size and shape of the pupil of the eye.
[0010] More recently, implantable devices have been developed for
providing pulsatile or intermittent doses of therapeutic agent to
the eye. Examples of such devices are disclosed in U.S. Pat. Nos.
5,725,493; 5,830,173; and 6,251,090 and U.S. Patent Publication No.
2008/0039792, all of which are specifically incorporated herein by
reference for all purposes.
[0011] U.S. Patent Application No. 2008/0181930 discloses a drug
delivery device having a body that includes a matrix of a
therapeutic agent and another material such as silicon. The body is
coated with a material such as parylene and one or more pores
extend from the outer surface of the coating to the outer surface
of the body to allow for release of therapeutic agent.
[0012] U.S. Provisional Patent Application No. 61/157,010, which is
incorporated herein by reference for all purposes, discloses a
pericorneal drug delivery device. A preferred embodiment of the
device includes an inner matrix core surrounded by an outer
coating. The outer coating includes one or more openings extending
to the core for allowing sustained drug release from the inner
matrix core.
[0013] Each of these devices can provide for some degree of
sustained delivery of an ophthalmic composition. However, these
devices, as well as other conventional devices, typically suffer
from one or more drawbacks. As one example, many conventional
devices require that they be applied through an invasive surgical
procedure. As another example, many conventional devices have
difficulty delivering desired amounts of therapeutic agent for
desired amounts of time. As another example, many conventional
devices have difficulty delivering therapeutic agent in particular
quantities at particular times as may be needed or desired. As yet
another example, many devices have difficulty maintaining their
desired location relative to the eye and can be lost or undesirably
moved. As still another example, many conventional devices can
cause discomfort. Thus, there is a need for an ophthalmic drug
delivery device that can overcome one, two or more of these
drawbacks.
SUMMARY OF THE INVENTION
[0014] The present invention is directed to an ophthalmic pulsatile
pericorneal drug delivery device. The device includes an annular
body sized and shaped to reside upon a conjunctiva of a human eye
and extend substantially entirely about a cornea of the human eye
when the annular body is disposed upon the human eye. The device
further includes a therapeutic composition associated with the
annular body. The therapeutic composition is preferably divided
into a plurality of separate and distinct units. The device also
includes at least one opening for releasing the therapeutic
composition wherein the therapeutic composition is released through
the at least one opening topically to the eye as multiple separate
doses through repeated release of one or more of a plurality of
separate and distinct units. In a preferred embodiment, the
therapeutic composition in divided into the plurality of separate
and distinct units within the device or annular body and/or prior
to release from the device.
[0015] The device, the annular body or both can include a contact
surface that is shaped and sized to correspond to and contact the
conjunctiva of the human eye upon application of the device to the
eye. That contact surface of the device including all portions that
contact the conjunctiva will typically have a surface area that is
at least 77 mm.sup.2 and is typically no greater than 220 mm.sup.2.
Preferably, the device has a volume that is at least at least 14
mm.sup.3 and is no greater than 100 mm.sup.3.
[0016] In one embodiment, the annular body includes a plurality of
separate reservoirs, each of the plurality of reservoirs containing
one of the separate and distinct unit of the plurality of units, In
such an embodiment, the device will also include a plurality of
openings separately and respectively associated with the plurality
of separate reservoirs for providing fluid communication to the
plurality of reservoirs and will includes a plurality of doors for
separately and respectively covering the plurality of openings.
Preferably each door of the plurality of doors is opened at a
separate and distinct point in time to provide for separate release
of the separate and distinct units over an extended period of time.
In one preferred embodiment, the plurality of doors are formed of
an erodible material that is configured to erode is a manner that
allows the distinct units to exit the annular body at separate and
distinct periods of time.
[0017] The present invention is also directed to a method of
treating an ophthalmic disease. Accordingly, the device can be
disposed upon the eye to intermittently release therapeutic
composition topically to the eye.
BRIEF DESCRIPTION OF THE DRAWINGS
[0018] The accompanying drawings, which are incorporated in and
constitute a part of this specification, illustrate several
embodiments of the invention and together with the description,
serve to explain the principles of the invention.
[0019] FIG. 1 is a perspective view of an exemplary peri-corneal
drug delivery device structure suitable for use with the invention
of the present application.
[0020] FIG. 2 is a perspective view of the structure of FIG. 1
shown as applied to an eye.
[0021] FIG. 3 is a perspective view of one embodiment of a
pulsatile peri-corneal drug delivery device in accordance with an
aspect of the present invention.
[0022] FIG. 4 is a perspective view of another embodiment of a
pulsatile peri-corneal drug delivery device in accordance with an
aspect of the present invention.
[0023] FIG. 5 is a perspective view of yet another embodiment of a
pulsatile peri-corneal drug delivery device in accordance with an
aspect of the present invention.
DETAILED DESCRIPTION OF THE INVENTION
[0024] The present invention is predicated upon the provision of a
pulsatile peri-corneal drug delivery device. The device is
typically annular and is configured to be disposed upon the
conjunctiva and/or cornea and, preferably, substantially extends
about and/or substantially surrounds the cornea. The device will
include a mechanism for assisting the device in providing pulsatile
release (i.e., release of separate and distinct units or doses) of
therapeutic composition to the eye, particularly the corneal
surface of the eye, of a mammal (e.g., a human being) from one or
more reservoirs of therapeutic composition. The mechanism will
typically allow for pulsatile release from a single reservoir or
multiple reservoirs of therapeutic composition.
[0025] In one embodiment, the pulsatile drug delivery device
includes either a single reservoir of therapeutic composition which
contains all of the doses of the therapeutic composition or
includes multiple reservoirs of therapeutic composition where each
of the multiple reservoirs includes multiple doses of therapeutic
composition. In such an embodiment, the mechanism for assisting in
providing pulsatile release will typically include one or more
openings that provide fluid communication between the reservoir[s]
and an environment external the device. The mechanism will also
typically include a door that can be selectively opened and closed
to allow release of the therapeutic composition from the
reservoir[s]. Preferably, the door[s] can be opened and closed to
allow for the release of multiple separate single doses of the
therapeutic composition over an extended time period.
[0026] In an alternative embodiment, the therapeutic composition is
divided within the device into multiple separate distinct units
wherein each of the units or a subset of the multiple units
preferably provides a single dose of therapeutic composition. In
such an embodiment, the mechanism for assisting in providing
pulsatile release will typically include one or more openings that
provide fluid communication between one or more reservoirs and an
environment external the device. The multiple separate units can be
located within a single reservoir or multiple reservoirs within the
device. For example, each unit of the multiple units may be located
within its distinct reservoir of multiple reservoirs of the device
and be releasable as a single dose. Alternatively, multiple units
may be located within a reservoir where each unit is separately
releasable from the device to form a single dose. In embodiments
where one unit or a subset of the multiple units are disposed in
multiple different reservoirs, the mechanism for assisting in
providing pulsatile release will typically include one or more
openings for each separate reservoir to provide fluid communication
thereto and one or more doors for at least temporarily prohibiting
and then subsequently allowing fluid communication between the
reservoir[s] and an environment external the device in embodiments
where the multiple different units are in a single reservoir, their
may only need be a single opening to provide for fluid
communication between the reservoir and an environment external the
device. Moreover, a door will typically be optional for prohibiting
and then subsequently allowing the fluid communication.
[0027] It should be understood, that the terms "separate" and
"distinct", as they apply to the units and doses of therapeutic
composition, have particular meaning for the devices of the present
invention. As they apply to units, those terms suggest there is an
identifiable physical element that separates the units. That
physical element could be a physical space that is between and
separates the units. Alternatively, that physical element could he
an interface where one of the units abuts the other. It is
contemplated that the "separate" and/or "distinct" units may be
connected to each other, however, the physical element dividing the
units from each other will always exist. Preferably, the units are
unconnected relative to each other and may not even contact each
other particularly while in the one or more reservoirs of the
device. As these terms apply to doses, they mean that one dose will
be substantially completely released (i.e., at least 90% and more
preferably at least 95% by weight of the therapeutic composition
has been released) to the environment external of the device, which
will typically be tear fluid or film external of the eye, before a
separate and/or distinct dose begins release to the environment
external of the device.
[0028] With reference to FIGS. 1 and 2, there is illustrated an
annular peri-corneal structure 10 that, as will be seen from the
description of the exemplary devices of FIGS. 3 through 5, can
serve as a base structure 10 into which the therapeutic composition
can be integrated. The device 10 is generally annular and, in the
embodiment illustrated, is annular about a central axis 18 and lies
in a plane 20 that is perpendicular to that axis. As used herein,
the term "annular" as it is used to describe the drug delivery
device or structure thereof does not require that the device be a
continuous uninterrupted ring but must form substantially an entire
ring that can sufficiently extend about the cornea and/or
conjunctiva of the eye to maintain the device upon the conjunctiva
once provided to an individual. Preferably the annular device forms
or substantially forms a ring (i.e., forms at least 60% and more
preferably at least 80% of a ring that is designed to extend about
the cornea). It should be understood that the area internal to the
annular device is typically entirely open allowing for clear
vision. However, it is contemplated that a material may be located
internal of the annular device. For example, a clear polymeric film
material (e.g., a contact lens material or material like a contact
lens) might be located internal of the annular device and connected
to the device.
[0029] In the embodiment shown, the structure 10 is in a continuous
ring or band having an inner diameter 22 and an outer diameter 24.
Moreover, the illustrated structure 10 is substantially or entirely
symmetrical about the central axis 18. The inner diameter is
typically configured to be directly adjacent the cornea upon
application of the device to the eye. A portion of the device may
reside upon the outer periphery of the cornea, but this is
typically not desired. The inner diameter of the device is
typically at least 0.3 centimeter (cm), more typically at least 0.6
cm and even more possibly at least 0.9 cm and is typically no
greater than 1.5, more typically no greater than 1.3 cm and even
more typically no greater than 1.1 cm. The outer diameter is
typically at least 0.6 cm, more typically at least 1.1 cm and even
more possibly at least 1.3 cm and is typically no greater than 2.2,
more typically no greater than 1.9 cm and even possibly no greater
than 1.7 cm. It should be understood that, for individuals with
smaller eyes such as children at ages approximately 3 to 10, these
sizes may be reduces by 5 to 20%.
[0030] The structure 10 generally has an outer surface 26. That
outer surface 26 includes a first surface 28, which is a contacting
surface that contacts the conjunctiva of the eye when the structure
10 is placed atop the conjunctiva. The structure 10, and
particularly the outer surface 26, also includes a second surface
30 that is opposite the first surface 28. The second surface 30 is
an outwardly facing surface that faces away from the conjunctiva
upon placement of the device 10 thereon. The first surface 28 can
be flat or slightly concave. The second surface 30 can be flat or
slight convex. Both the first surface 28 and the second surface 30
are disposed at an angle 34 relative to the plane 20 in which the
device 10 lies. That angle 34 may be different for different
portions of the surface[s] 26, 28, but is typically at least about
3.degree., more typically at least about 10.degree. and even
possibly at least about 20.degree. and is also typically no greater
than about 60.degree., more typically no greater than about
45.degree. and even possibly no greater than about 30.degree..
[0031] The structure of the device is preferably formed of a
non-biodegradable polymer that is substantially or entirely
impermeable to the therapeutic composition. Examples of potential
materials suitable for the structure include, without limitation,
ethylene vinyl acetate (EVA), polyacrylic materials (e.g., PMMA),
silicone, polyimide, polytetrafluoroethylene (PTFE), combination
thereof or the like. In a highly preferred embodiment, the
structure is formed of parylene. As used herein, "substantially
impermeable" as it applies to the structure material and the
therapeutic composition means that less than 5% and more typically
less than 2% of the therapeutic composition permeates into the
structure material during the use of the device once applied to an
eye of an individual.
[0032] With reference to FIG. 3, there is illustrated one exemplary
embodiment of a pulsatile peri-corneal drug delivery device 40 in
accordance with the present invention. As can be seen, the device
40 has the structure 10 substantially described relative to FIGS. 1
and 2. The device 40 includes multiple reservoirs 42 that each
contains a separate and distinct unit 44 of therapeutic
composition. Each of the reservoirs 42 is also associated with an
opening 46 that can provide for fluid communication between the
reservoir 42 and the environment external of the reservoir 42 and
the device 40. A plurality of doors 48 is then associated
respectively with each of the plurality of openings 46 for
controlling flow of fluid through the openings 46. The device 40
also includes an electrical supply 48 (e.g., a battery or battery
and controller) and electrical connections 50 that connect to the
electrical supply 48 and are connected to or associated with the
doors 48.
[0033] Typically, the device 40 will include at least 3, more
typically at least 10, even more typically at least 60 and even
more typically at least 180 and even possibly at least 360 or even
at least 600 units 44.
[0034] In operation (i.e., after application of the device to an
eye of a mammal, particularly a human being), the electrical supply
sends electrical current through the connections 50. That
electrical current then opens the doors 48 to allow fluid
communication between the reservoirs 42 and the environment outside
the device 40 to allow the distinct units 44 to be separately
released as doses of therapeutic composition at separate points in
time. Preferably, each door 48 is configured to allow such fluid
communication starting at a separate and distinct point in time.
For example, after a first door 48 of the multiple doors 48 opens
to provide such fluid communication, each subsequently opening door
48 of the remaining multiple doors 48 will provide such fluid
communication at least 60 minutes, more typically at least 8 hours,
still more typically at least 10 hours and even possibly at least
20 or even 30 hours after a previously opening door 48 of the
multiple doors 48 provides such fluid communication. Such a
progression of opening doors 48 will typically continue over an
extended period of time.
[0035] It is contemplated that the electrical current may open the
doors by a variety of mechanisms. Typically, the electrical
connections will include an anode and cathode that can induce a
charge on opposite side of the door and/or can run the electrical
current through the door. In that instance, the doors may be formed
of material that erodes or melts upon exposure to the electrical
current. Alternatively, the doors could be formed of a material
that is drawn toward the anode or cathode upon exposure to
electrical charge. The doors could also be formed of a material
(e.g., a metal or polymeric material) that vaporizes upon exposure
to electrical current or charge.
[0036] With reference to FIG. 4, there is illustrated another
exemplary embodiment of a pulsatile peri-corneal drug delivery
device 60 in accordance with the present invention. As can be seen,
the device 60 has the structure 10 substantially described relative
to Figs. I and 2. The device 60 includes multiple reservoirs 62
that each contains a separate and distinct unit 64 of therapeutic
composition. Each of the reservoirs 62 is also associated with an
opening 66 that can provide for fluid communication between the
reservoir 62 and the environment external of the reservoir 62 and
the device 60. Each of the openings 66 is initially blocked from
such fluid communication by a door 68.
[0037] In FIG. 4, each of the doors 68 is formed of a bio-erodible
material. Examples of such bio-erodible materials include, without
limitation, polylactic acids, polyglycolic acids,
polylactic-glycolic acids, poly caprolactones, triglycerides,
polyethylene glycols, poly orthoesters, poly anhydrides,
polyesters, cellulosics and combinations thereof Moreover, such
materials may be applied and may be applied in one or multiple
layers by a variety of techniques such as coatings, brushing or the
like. In one preferred embodiment, the material of the doors is
applied in multiple layers by repeat spray coating and/or drying.
It is noted that the doors 68 shown in FIG. 4 are shown in a
magnified manner to show them as having different layers. However,
it should be understood that the layers will not typically extend
outwardly any significant distance from the annular body of the
device and are preferably located within the openings 66 to the
reservoirs 62.
[0038] In operation (i.e., after application of the device to an
eye of a mammal, particularly a human being), the doors 68 erode
away to allow fluid communication between the reservoirs 62 and the
environment outside the device 60 to allow the distinct units 64 to
be separately released as doses of therapeutic composition at
separate points in time. Preferably, each door 68 is configured to
allow such fluid communication starting at a separate and distinct
point in time. For example, after a first door 68 of the multiple
doors 68 opens to provide such fluid communication, each
subsequently opening door 68 of the remaining multiple doors 68
will provide such fluid communication at least 60 minutes, more
typically at least 8 hours, still more typically at least 10 hours
and even possibly at least 20 or even 30 hours after a previously
opening door 68 of the multiple doors 68 provides such fluid
communication. Such a progression of opening doors 68 will
typically continue over an extended period of time.
[0039] In the embodiment shown, each of the doors 68 is shown to
have a different thickness. In this manner, the bioerodible
material of the doors 68 is configured to allow for fluid
communication as described in the preceding paragraph. Preferably,
the first door 68 to allow fluid communication will have a
thickness (T.sub.1). Then each subsequently opening door will have
a thickness according to the following equation:
T=T.sub.1(N+1)F
[0040] wherein:
[0041] (N) is number of doors 68 that are, or are configured to
open and provide or allow fluid communication prior to that
subsequently opening door 68; and
[0042] (F) is any number greater than 0.1 but less than 10 and may
be different for each subsequently opening door.
[0043] It should be understood that (F) is a variable of the
equation that allows for variations in bio-erosion rates and/or
preselected pattern of release of the units of therapeutic
composition. Typically, the device will include at least 3, more
typically at least 10, even more typically at least 60 and even
more typically at least 180 and even possibly at least 360 or even
at least 600 units 44 and/or reservoirs 42.
[0044] With reference to FIG. 5, there is illustrated yet another
exemplary embodiment of a pulsatile peri-corneal drug delivery
device 80 in accordance with the present invention. As can be seen,
the device 80 has the structure 10 substantially described relative
to FIGS. 1 and 2. The device 80 includes multiple distinct units 82
of therapeutic composition located within a single annular
reservoir 84 that extends substantially entirely about the
structure 10. As can be seen, the units are unconnected relative to
each other. As can be seen, the distinct units 82 are distributed
along the reservoir 84 one after the other. In the particular
embodiment shown, spacer units 86 separate the distinct units 82
from each other. When used, the spacer units 86 can aid discrete
and separate dispensing and delivery of the distinct units 82 of
therapeutic composition.
[0045] The device 80 of FIG. 5 also includes an opening 90 and an
electromechanical mechanism 92 for providing for fluid
communication between at least a portion of the reservoir 84 and
the environment external of the reservoir 84 and the device 80. As
can be seen, the electromechanical mechanism 92 can move the
discrete units 82 and/or the spacer units 86 about the reservoir 84
to individually align each discrete unit 82 with the opening 90.
Once a discrete unit 82 has been aligned with the opening 90, fluid
communication between the reservoir 84 and the external environment
of the device 80 through the opening 90 allows the discrete unit 82
to release its therapeutic composition to that external environment
(e.g., tear fluid can enter the reservoir 84 through the opening 90
to allow for such release). Preferably, the electromechanical
mechanism 92 is pre-programmed to move the units 82 a separate
distinct points in time.
[0046] The discrete units 82 can be formed in a variety of
configurations that will allow them to relatively rapidly release
therapeutic composition when the unit 82 is aligned with the
opening 90. In a preferred embodiment, the discrete units are
comprised of a non-biodegradable material (e.g., polymeric
material) that includes one or more openings and or reservoirs for
containing and then releasing the therapeutic composition. As one
example, the discrete unit 82 can comprise a shell (e.g., a
polymeric shell) substantially surrounding a reservoir, which
contains the therapeutic composition in a solid, but dissolvable,
form. In such an embodiment the shell will typically include one or
more openings such that fluid (e.g., tear fluid) can enter the
opening[s] and/or reservoir and dissolve the therapeutic
composition, which can then be released from the polymeric shell.
As another example, the discrete unit 82 comprises a non-erodible
body that has a coating of therapeutic composition on it and fluid
(e.g., tear fluid) can dissolve the therapeutic composition, which
can then be released from the body. In such an embodiment, the
coating of therapeutic composition could include a polymeric
material that is either erodible or non-erodible, but which can aid
in controlling the rate of release of the therapeutic composition
from the distinct unit. As still another example, the discrete unit
82 comprises a non-erodible matrix (e.g., polymeric matrix) within
which a therapeutic composition has been dispersed. In such an
embodiment, the therapeutic composition can permeate out of the
matrix when it is exposed to fluid (e.g., tear fluid) adjacent the
opening of the device. Typically, the device 80 will include at
least 3, more typically at least 10, even more typically at least
60 and even more typically at least 180 and even possibly at least
360 or even at least 600 units 84.
[0047] A variety of mechanisms may be suitable for use as the
electromechanical mechanism 92 for the device 80. For example, a
small electrical powered gear system might be used to advance the
units 82. Alternatively, a small magnetic system could be used to
advance the units 82. Preferably, the mechanism includes a
controller for controlling the system such that it advances the
units 82 at predetermined times.
[0048] In operation (Le., after application of the device to an eye
of a mammal, particularly a human being), the discrete units 82 are
individually moved to the opening 90 to progressively allow fluid
communication between each of the units 82 and the environment
outside the device 80 to allow the distinct units 82 to separately
release doses of therapeutic composition at separate points in
time. Preferably, each of the units 82 are moved about the
reservoir 84 to align one of the units with the opening 82 at
distinct points in time that are at least 60 minutes, more
typically at least 8 hours, still more typically at least 10 hours
and even possibly at least 20 or even 30 hours apart from each
other to allow each of the units to release therapeutic composition
to the environment outside the device 80. Such a progression of
release from the units 82 will typically continue over an extended
period of time.
[0049] In an alternative configuration, it is contemplated that the
device of the present invention can configured substantially
identical to the device 80 of FIG. 5 with minor exceptions. The
therapeutic composition can be provided as a single, preferably
liquid, mass or supply that can be released through the opening 90
as separate and distinct units. In such an embodiment, the flow
through the opening would be controlled by a door or valve that
would allow for release of portions of the single mass or supply of
therapeutic compositions at separate points in time to form the
separate and distinct doses or units.
[0050] The therapeutic composition of the present invention will
typically include a therapeutic agent and may be consist or consist
essentially of only therapeutic agent. Alternatively, the
therapeutic composition can include one or more excipients such as,
surfactant, tonicity agent, carrier such as water, polymeric
material (e.g., biodegradable polymeric material), antimicrobial
agent, buffering agents, combinations thereof or the like. The
therapeutic composition may be provided as a liquid, semi-solid or
solid, which will typically depend upon the type of discrete units,
door[s] and/or reservoir[s] used with the device. Preferably, the
therapeutic composition, particularly the therapeutic agent, is in
a condition that allows it to, upon release from the device to the
environment external the eye (e.g., to the tear fluid). The
therapeutic composition, particularly the therapeutic agent, can
then move with the tear fluid to the conjunctiva and/or to the
cornea and/or to the back of the eye. The therapeutic composition,
particularly the therapeutic agent, can then penetrate into the eye
or treat a surface disease of the eye.
[0051] The therapeutic agent (e.g., ophthalmic drug) may be any
therapeutic agent, so long as the therapeutic agent is capable of
providing a therapeutic effect to the eye of a mammal, particularly
a human. In particular embodiments, the therapeutic compound is a
compound that can be applied for the treatment of an ophthalmic
disorder. For example, the therapeutic compound may be a glaucoma
medication, an antimicrobial medication, an anti-inflammatory
medication, or a dry-eye syndrome medication, or a therapeutic
compound that can be applied in the treatment of diabetic
retinopathy or age-related macular degeneration.
[0052] Ophthalmic drugs, such as prostaglandins, triamcinolone,
15-HETE (Icomucret), anti-inflammatories (non-steroidal
anti-inflammatory drugs (NSAIDs)) receptor tyrosine kinase
inhibitors (RTKi), timolol maleate, fluoroquinolones (e.g.,
moxifloxacin) and rimexolone, are well suited for delivery with the
devices of the present invention. The prostaglandin may be a
natural or a synthetic prostaglandin. Non-limiting examples of
prostaglandins include cloprostenol, fluprostenol, latanoprost,
travoprost, and unoprostone.
[0053] It is also contemplated that the device of the present
invention may be use to deliver multiple therapeutic agents. For
example, for one device, a first one or subset of the distinct
doses or units may include a therapeutic composition having a
different therapeutic agent than another second one or subset or
subset of distinct doses or units. Moreover, those units can be
delivered at any distinct points in time to provide a desired
therapy.
[0054] According to certain aspects of the present invention, the
opening[s] that allow for fluid communication to the reservoir[s]
and/or therapeutic composition are located only on the surface of
the device that contacts the conjunctiva of the eye. Alternatively,
the opening[s] can be located only on the surface facing away from
the conjunctiva of the eye. As still another alternative,
opening[s] may be located on both surfaces. Having opening[s]
facing away from the conjunctiva can be particularly desirable for
delivery of anti-glaucoma or intraocular pressure lowering
therapeutic agents such as a prostaglandin (e.g., cloprostenol,
fluprostenol, latanoprost, travoprost, and unoprostone). This
allows the therapeutic agent to diffuse into the tear fluid and
from the tear fluid through the cornea to the iris ciliary body.
Having opening[s] that face arid/or contact the conjunctiva can be
particularly desirable for therapeutic agents that act at the
posterior of the eye and can benefit from improved delivery to the
vitreous. Such drugs can include anti-inflammatories, particularly
NSAIDs such as nepafenac or diclofenac.
[0055] In certain aspects, the devices of the present invention
deliver multiple separate therapeutically effective doses of the
therapeutic composition to a mammal, particularly a human being,
over an extended time period. As used herein, the phrase "extended
time period" is no less than 12 hours, but is typically at least
about 24 hours, at least about 5 days, at least about 20 days, at
least about 30 days, at least about 60 days, at least about 90
days, at least about 120 days, at least about 180 days, at least
about 240 days or any range derivable therein. In particular
embodiments, the devices of the present invention deliver the
therapeutically effective doses of the therapeutic composition for
at least 10 days.
[0056] Advantageously, the device of the present invention can
provide desirable dosage amounts of therapeutic agent during the
above referenced extended time periods. Generally, the device can
typically deliver doses that includes at least 0.01 .mu.g, more
typically at least 0.1 .mu.g and even more typically at least 0.6
.mu.g of therapeutic agent per dose or distinct unit. The device
also typically delivers no greater than 1000 .mu.g, more typically
no greater than 400 .mu.g and still more typically no greater than
150 .mu.g of therapeutic agent per dose or distinct unit. For
higher potency drugs such as prostaglandins, the device is
typically configured to deliver from about 0.4 .mu.g to about 2.0
.mu.g of therapeutic agent per dose or distinct unit. For medium
potency drugs, the device is typically configured to deliver from
about 5 to about 20 .mu.g. For lower potency drugs, the device is
typically configured to deliver from about 30 .mu.g to about 120
.mu.g of therapeutic agent per dose or distinct unit.
[0057] In one embodiment, the present invention provides a method
of treating an ocular disorder in a subject comprising: (a) forming
a drug delivery device as described herein for the sustained
release of multiple separate doses of therapeutic composition to
the eye; and (b) disposing the device upon an external surface
(e.g., surface of the conjunctiva) of the eye. The method can be
specifically for treating glaucoma or ocular hypertension in a
subject (e.g., a human) and the therapeutic agent can be, for
example, a prostaglandin.
[0058] In some embodiments, biodegradable microspheres of the
therapeutic agent are formed for creating the whole or a part of
the therapeutic composition. Microspheres, microcapsules and
nanospheres (collectively, "microspheres") are generally accepted
as particles with diameters ranging from approximately 50 nm to
1000 micrometers. They are reservoir devices that come in a variety
of different forms, including, but not limited to, porous, hollow,
coated, or uncoated forms with a pharmaceutically active agent
either incorporated into or encapsulated by polymeric material via
numerous known methods. Such known methods include, but are not
limited to, spray drying, spinning disk and emulsification methods.
Microspheres may be formed from a myriad of polymeric materials
selected from, but not limited to, polylactic acids, polyglycolic
acids, polylactic-glycolic acids, poly caprolactones,
triglycerides, polyethylene glycols, poly orthoesters, poly
anhydrides, polyesters, cellulosics and combinations thereof. The
amount of therapeutic agent incorporated or encapsulated in the
microsphere is generally between 0.001% and about 50%.
[0059] The device can be configured to have a relatively large
external surface area, which allows the device to be maintained
upon the conjunctiva more securely. In particular, capillary forces
of the fluid upon the conjunctiva can aid in maintaining the device
upon the eye. It should be noted that, for purposes of this
invention, the fluid located upon the conjunctiva is considered to
be part of the conjunctiva upon which the device can be located.
The surface area of the contacting surface as determined inclusive
of any and every portion (including haptics) of the device that
contacts the conjunctiva is typically at least 50 (millimeters
squared) mm.sup.2, more typically at least 77 mm.sup.2, even more
typically at least 90 mm.sup.2 and even possibly at least 110
mm.sup.2 and the surface area of that portion is typically no
greater than 320 mm.sup.2, more typically no greater than 220
mm.sup.2, even more possibly no greater than 170 mm.sup.2 and even
possibly no greater than 120 mm.sup.2.
[0060] Advantageously, it may be the case that the device of the
present invention can reside upon and be maintained upon the eye
without needing any fastening elements such as stitches or other
mechanical devices that extend into the eye (i.e. into the
conjunctiva, cornea or any other portion of the eyeball). Such
fastening devices typically must be surgically applied and
avoidance of such surgical applications can be desirable in many
circumstances.
[0061] The device of the present invention can, in certain
embodiments, be relatively large such that it can include multiple
doses or distinct units of therapeutic composition. The volume of
the entire device of the present invention is typically at least 10
mm.sup.3, more typically at least 14 mm.sup.3, and even more
typically at least 18 mm.sup.3 and the volume of the device is
typically no greater than 100 mm.sup.3, more typically no greater
than 50 mm.sup.3, and even possibly no greater than 30 mm.sup.3.
The weight of the entire device of the present invention is
typically at least 10 mg, more typically at least 14 mg, and even
more typically at least 17 mg and the weight of the device is
typically no greater than 1000 mg, more typically no greater than
100 mg, and even more possibly no greater than 30 mg.
[0062] The use of the term "or" in the claims is used to mean
"and/or" unless explicitly indicated to refer to alternatives only
or the alternatives are mutually exclusive.
[0063] Throughout this application, the term "about" is used to
indicate that a value includes the standard deviation of error for
the device or method being employed to determine the value.
[0064] Following long-standing patent law, the words "a" and "an,"
when used in conjunction with the word "comprising" in the claims
or specification, denotes one or more, unless specifically
noted.
[0065] In this document (including the claims), the terms
"comprise" (and any form of comprise, such as "comprises" and
"comprising"), "have" (and any form of have, such as "has" and
"having"), and "include" (and any form of include, such as
"includes" and "including") are open-ended linking verbs.
[0066] Applicants specifically incorporate the entire contents of
all cited references in this disclosure. Further, when an amount,
concentration, or other value or parameter is given as either a
range, preferred range, or a list of upper preferable values and
lower preferable values, this is to be understood as specifically
disclosing all ranges formed from any pair of any upper range limit
or preferred value and any lower range limit or preferred value,
regardless of whether ranges are separately disclosed. Where a
range of numerical values is recited herein, unless otherwise
stated, the range is intended to include the endpoints thereof, and
all integers and fractions within the range. It is not intended
that the scope of the invention be limited to the specific values
recited when defining a range.
[0067] Other embodiments of the present invention will be apparent
to those skilled in the art from consideration of the present
specification and practice of the present invention disclosed
herein. It is intended that the present specification and examples
be considered as exemplary only with a true scope and spirit of the
to invention being indicated by the following claims and
equivalents thereof.
* * * * *